Ollin Biosciences
Ollin Biosciences is a clinical-stage biopharmaceutical company developing bispecific antibody therapies for vision-threatening eye diseases, including OLN324 (VEGF/Ang2) for diabetic macular edema and wet AMD, and OLN102 (IGF-1R/TSHR) for thyroid eye disease.
- Company typePrivate
- Founded2023
- HeadquartersAustin, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Ollin Biosciences does
Ollin Biosciences is a clinical-stage biopharmaceutical company founded in 2023 and headquartered in Austin, Texas, that develops bispecific antibody therapies for vision-threatening eye diseases. Its portfolio comprises two core programs: OLN324, a higher-potency, small-format VEGF/Ang2 bispecific antibody advancing to Phase 3 for diabetic macular edema (DME) and wet age-related macular degeneration (wet AMD), and OLN102, a first-in-class IGF-1R/TSHR bispecific antibody in IND-enabling stage for thyroid eye disease. The company emerged from stealth in September 2025 and is led by Co-Founder and CEO Jason Ehrlich, M.D., Ph.D., a former Genentech executive, supported by a nine-person executive team covering translational sciences, biology, clinical development, clinical operations, portfolio, and corporate development.
In a 164-patient Phase 1b JADE head-to-head study, OLN324 demonstrated faster and greater retinal anatomy improvements than faricimab (Vabysmo), including approximately 50% greater reductions in pigment epithelial detachment thickness in wet AMD, a +2.2 letter visual acuity advantage at week 20, 93% of DME patients on 4mg completing 12 weeks without retreatment versus 89% on faricimab, nearly 90% achieving absence of DME at week 12 versus 57% for faricimab, and zero cases of intraocular inflammation. Both the FDA and EMA have provided constructive feedback on the Phase 3 trial design, which is planned to initiate in the second half of 2026.
Ollin has raised approximately $430 million in private capital, comprising a $100 million round in September 2025 and an oversubscribed $330 million Series B in June 2026 co-led by TCGX and ARCH Venture Partners, with participation from a16z Bio+Health, Blackstone, CPP Investments, RA Capital Management, Mubadala Capital, Monograph Capital, and T. Rowe Price Investment Management. In June 2026, Ollin entered a strategic development and commercialization partnership with Innovent Biologics for IBI324 (OLN324), enabling Phase 3 expansion into China and South Korea. As a clinical-stage company with no commercialized products, Ollin generates no product revenue and addresses an estimated $15 billion worldwide retina therapeutics market opportunity, with a combined addressable market across OLN324, IBI363, and IBI343 exceeding $60 billion per company-supplied commentary.
Ollin Biosciences firmographics
Firmographics- Name
- Ollin Biosciences
- Legal name
- Ollin Biosciences, Inc.
- Website
- https://ollin.bio
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Ollin Biosciences is a clinical-stage biopharmaceutical company developing bispecific antibody therapies for vision-threatening eye diseases, including OLN324 (VEGF/Ang2) for diabetic macular edema and wet AMD, and OLN102 (IGF-1R/TSHR) for thyroid eye disease.
- Ownership category
- akta.pro rank
Ollin Biosciences industry classification
Industry- Product category
- Ophthalmic Biopharmaceuticals
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Ophthalmology Pharmaceuticals (HLAIAAAL)
- akta.pro secondary industries
- Ophthalmology Specialty Pharmaceuticals (HLAIACAK), Rare Ophthalmology Disorder Therapies (HLAIAIAK)
Keywords
Where Ollin Biosciences is headquartered
LocationHeadquarters
- HQ city
- Austin
- HQ country
- United States
- HQ region
- North America
Markets served
Ollin Biosciences business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Distribution channels1 record
Marketing channels3 records
Ollin Biosciences product offering
Product offeringCore offering
Ollin Biosciences is a clinical-stage biopharmaceutical company developing a pipeline of proprietary bispecific antibody drug candidates for vision-threatening eye diseases. Its lead asset OLN324 is a higher-potency, small-format VEGF/Ang2 bispecific antibody in Phase 3 development for diabetic macular edema and wet age-related macular degeneration, and its second asset OLN102 is a first-in-class IGF-1R/TSHR bispecific antibody in IND-enabling stage for thyroid eye disease.
Product overview
Ollin Biosciences is a clinical-stage biopharmaceutical company developing a differentiated pipeline of drug candidates for vision-threatening eye diseases. The company's portfolio consists of two core therapeutic programs: OLN324, a next-generation VEGF/Ang2 bispecific antibody in Phase 3 for diabetic macular edema and wet age-related macular degeneration, and OLN102, a first-in-class IGF-1R/TSHR bispecific antibody in IND-enabling stage for thyroid eye disease. Both candidates build from validated biology to target serious ophthalmic conditions.
Differentiator
Problem solved
Functional benefit
Products and services
- OLN324 Higher potency, small format VEGF/Ang2 bispecific antibody in Phase 3 development for diabetic macular edema and wet age-related macular degeneration, developed for patients with vision-threatening retinal diseases and for biopharmaceutical partners seeking a differentiated ophthalmology biologic.
- OLN102 First-in-class IGF-1R/TSHR bispecific antibody in IND-enabling stage for thyroid eye disease, developed for patients with limited treatment options in this ophthalmic indication.
Quantifiable outcome
- 93% of patients on OLN324 4mg completed 12 weeks without retreatment vs 89% on faricimab in DME
- +4 more outcomes
Companies that use Ollin Biosciences
Customer profileSegments1 record
Ideal customer profiles1 record
Ollin Biosciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Ollin Biosciences partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Innovent BiologicscoreStrategic partnership with Innovent Biologics for the development and commercialization of IBI324 (OLN324). The partnership enables global Phase 3 trials including China and South Korea, with OLN324 being advanced as a next-generation VEGF/Ang2 bispecific antibody for diabetic macular edema and wet age-related macular degeneration.
Scale indicators5 records
Recent moves6 records
Expansion highlights6 records
Ollin Biosciences competitors and assessment
Company assessmentBroad incumbents
- Genentech (Roche): Developer of faricimab (Vabysmo), the established VEGF/Ang2 bispecific antibody that OLN324 was designed to beat in head-to-head trials. Most direct large-pharma incumbent competing for the same retina therapeutics market.
- Regeneron Pharmaceuticals: Markets Eylea and Eylea HD (aflibercept), the dominant anti-VEGF franchise in DME and wet AMD. Represents the entrenched standard of care that any new retina therapeutic must displace.
- Apellis Pharmaceuticals: Markets Syfovre (pegcetacoplan) for geographic atrophy; broader ophthalmology commercial player. While focused on complement rather than VEGF, Apellis represents a competing ophthalmology biopharmaceutical company with commercial infrastructure.
- Coherus BioSciences: Markets ophthalmology biosimilars including Cimerli (ranibizumab biosimilar) and is developing additional retina biosimilars. Competes on price in the same anti-VEGF retina therapeutics market.
Direct peers
- Kodiak Sciences: Clinical-stage biotech developing novel biologics for retinal diseases, including ABC platform candidates targeting VEGF-mediated ophthalmology indications — directly comparable clinical-stage anti-VEGF developer.
- Opthea: Clinical-stage company developing sozinibercept, a novel anti-VEGF-C/D therapy for wet AMD. Competes in the same retinal vascular indication space as Ollin's OLN324.
Emerging players
- Adverum Biotechnologies: Gene therapy company developing ADVM-022 (intravitreal aflibercept gene therapy) for wet AMD and DME — addresses the same patient population with a different therapeutic modality targeting anti-VEGF biology.
- Outlook Therapeutics: Developed LYTENAVA (ONS-5010), an ophthalmic formulation of bevacizumab for wet AMD. Competes for share of retina therapeutics market with a biosimilar-adjacent anti-VEGF approach.
- Ocular Therapeutix: Clinical and commercial-stage ophthalmology company developing sustained-release therapies including anti-VEGF programs for retinal disease. Directly comparable clinical-stage retina therapeutics developer.
- Annexon: Clinical-stage biotech developing complement-based therapies for retinal diseases including geographic atrophy. Comparable clinical-stage ophthalmology biopharmaceutical company pursuing novel mechanisms in serious eye diseases.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
Ollin Biosciences social profiles
Digital presenceOllin Biosciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Ollin Biosciences leadership team
Management profileNumber of profiles
Profiles9 records
Ollin Biosciences funding detail
Funding detailFunding overview
Funding rounds2 records
Investors10 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Ollin Biosciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Ollin Biosciences
What does Ollin Biosciences do?
Ollin Biosciences is a clinical-stage biopharmaceutical company developing a pipeline of proprietary bispecific antibody drug candidates for vision-threatening eye diseases. Its lead asset OLN324 is a higher-potency, small-format VEGF/Ang2 bispecific antibody in Phase 3 development for diabetic macular edema and wet age-related macular degeneration, and its second asset OLN102 is a first-in-class IGF-1R/TSHR bispecific antibody in IND-enabling stage for thyroid eye disease.
Is Ollin Biosciences a public or private company?
Ollin Biosciences is a private company. It is classified as venture growth investor backed and is currently operating.
When was Ollin Biosciences founded?
Ollin Biosciences was founded in 2023. It employs 11 to 50 people.
Where is Ollin Biosciences based?
Ollin Biosciences is headquartered in Austin, United States, in the North America region.
Who are Ollin Biosciences's main competitors?
Broad incumbents on record are Genentech (Roche), Regeneron Pharmaceuticals, Apellis Pharmaceuticals and Coherus BioSciences. Direct peers are Kodiak Sciences and Opthea. Emerging players are Adverum Biotechnologies, Outlook Therapeutics, Ocular Therapeutix and Annexon.
Does Ollin Biosciences have an API?
No public API is recorded for Ollin Biosciences.
What industry is Ollin Biosciences in?
Ollin Biosciences's product category is Ophthalmic Biopharmaceuticals. Its primary akta.pro industry code is HLAIAAAL, Ophthalmology Pharmaceuticals, with a secondary code of HLAIACAK, Ophthalmology Specialty Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2836.